Vitamin D decreases CD40L gene expression in ulcerative colitis patients: A randomized, double-blinded, placebo-controlled trial

Honarvar, Mohammad Reza; Nikniaz, zeinab; Sharifi, Amrollah; Hosseinzadeh-Attar, Mohammad Javad; Vahedi, Homayoon; yousefi rad, esmaeil; Amiriani, Taghi

doi:10.5152/tjg.2020.181028

Vitamin D decreases CD40L gene expression in ulcerative colitis patients: A randomized, double-blinded, placebo-controlled trial

Amrollah SHARIFI, (Golestan University of Medical Sciences (GOUMS), School of Health, Golestan Research Center of Gastroenterology and Hepatology (GRCGH), Iran)

Homayoon VAHEDİ, (Tehran University of Medical Sciences, Shariati Hospital, Digestive Research Institute, Digestive Disease Research Center, Iran)

Mohammad Reza HONARVAR, (Golestan University of Medical Sciences, School of Health, Health Management and Social Development Research Center, Iran)

Taghi AMIRIANI, (Golestan University of Medical Sciences (GOUMS), School of Health, Golestan Research Center of Gastroenterology and Hepatology (GRCGH), Iran)

Zeinab NIKNIAZ, (Tabriz University of Medical Sciences, School of Health, Gastrointestinal Diseases Research Center, Iran)

Esmaeil Yousefi RAD, (Lorestan University of Medical Sciences, School of Health, Nutritional Health Research Center, Iran)

Mohammad Javad HOSSEINZADEH-ATTAR (Tehran University of Medical Sciences, School of Nutritional Sciences and Dietetics, Department of Clinical Nutrition, Iran)

Turkish Journal of Gastroenterology

1 0

Yıl: 2020 Cilt: 31 Sayı: 2 Sayfa Aralığı: 99 - 104 Metin Dili: İngilizce DOI: 10.5152/tjg.2020.181028 İndeks Tarihi: 09-06-2021

Vitamin D decreases CD40L gene expression in ulcerative colitis patients: A randomized, double-blinded, placebo-controlled trial

Öz:

Background/Aims: The interaction of CD40 ligand (CD40L) and CD40 triggers the induction of pro-inflammatory cytokines. It has been proposed that vitamin D deficiency might be an important factor, which causes or aggregates the autoimmune situations. The aim of the present study was to assess the effect of vitamin D on CD40L gene expression in patients with ulcerative colitis (UC). Materials and Methods: Ninety mild-to-moderate UC patients were randomized to receive a single injection of 7.5 mg cholecalciferol or 1 mL normal saline. At baseline and 90 days following the intervention, RNA samples from whole blood were obtained. Fold changes in CD40L mRNA expression were determined for each patient using the 2-ΔΔCq method. The data were analyzed. Results: The serum levels of vitamin D and calcium increased only in the vitamin D group (p<0.05). Relative to baseline values, the CD40L gene expression fold change was significantly lower in the vitamin D group compared with the placebo group (median±interquartile range: 0.34±0.30 vs 0.43±1.20, respectively, p=0.016). Conclusion: The results of this study showed that vitamin D administration in mild-to-moderate UC patients led to the downregulation of the CD40L gene, which is an essential part of inflammatory pathways.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol 2014; 20: 91-9.
2. Lederman S, Yellin MJ, Krichevsky A, Belko J, Lee JJ, Chess L. Iden tification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (help). J Exp Med 1992; 175: 1091-101.
3. Almerighi C, Sinistro A, Cavazza A, Ciaprini C, Rocchi G, Bergamini A. 1α, 25-dihydroxyvitamin D3 inhibits CD40L-induced pro-inflam matory and immunomodulatory activity in human monocytes. Cyto kine 2009; 45: 190-7.
4. Ludwiczek O, Kaser A, Tilg H. Plasma levels of soluble CD40 li gand are elevated in inflammatory bowel diseases. Int J Colorectal Dis 2003; 18: 142-7.
5. Danese S, Katz JA, Saibeni S, et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 2003; 52: 1435-41.
6. Grammer AC, Slota R, Fischer R, et al. Abnormal germinal center re actions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 2003; 112: 1506-20.
7. Grammer AC, Slota R, Fischer R, et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by block ade of CD154-CD40 interactions. J Clin Invest; 117: 835.
8. Boumpas DT, Furie R, Manzi S, et al. A short course of BG9588 (an ti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003; 48: 719-27.
9. Stuber E, Strober W, Neurath M. Blocking the CD40L-CD40 in teraction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J Exp Med 1996; 183: 693-8.
10. Yu QT, Saruta M, Papadakis KA. Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Clin Immunol (Orlando, Fla) 2008; 127: 322-9.
11. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-81.
12. Sharifi A, Nedjat S, Vahedi H, Veghari G, Hosseinzadeh-Attar MJ. Vitamin D Status and Its Relation to Inflammatory Markers in Pa tients with Mild to Moderate Ulcerative Colitis. Middle East J Dig Dis 2018; 10: 84-9.
13. Aranow C. Vitamin D and the immune system. J Investig Med 2011; 59: 881-6.
14. Canning MO, Grotenhuis K, de Wit H, Ruwhof C, Drexhage HA. 1-alpha,25-Dihydroxyvitamin D3 (1,25(OH)(2)D(3)) hampers the maturation of fully active immature dendritic cells from monocytes. Eur J Endocrinol 2001; 145: 351-7.
15. Mahon BD, Wittke A, Weaver V, Cantorna MT. The targets of vi tamin D depend on the differentiation and activation status of CD4 positive T cells. J Cell Biochem 2003; 89: 922-32.
16. Kamen DL, Tangpricha V. Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity. Journal of molecular medicine (Berlin, Germany) 2010; 88: 441-50.
17. Froicu M, Weaver V, Wynn TA, McDowell MA, Welsh JE, Cantorna MT. A crucial role for the vitamin D receptor in experimental inflam matory bowel diseases. Mol Endocrinol 2003; 17: 2386-92.
18. Sharifi A, Hosseinzadeh-Attar MJ, Vahedi H, Nedjat S. A random ized controlled trial on the effect of vitamin D3 on inflammation and cathelicidin gene expression in ulcerative colitis patients. Saudi J Gastroenterol 2016; 22: 316-23.
19. Ledderose C, Heyn J, Limbeck E, Kreth S. Selection of reliable ref erence genes for quantitative real-time PCR in human T cells and neutrophils. BMC Res Notes 2011; 4: 427.
20. Pereira F, Barbachano A, Singh PK, Campbell MJ, Munoz A, Lar riba MJ. Vitamin D has wide regulatory effects on histone demethy lase genes. Cell Cycle 2012; 11: 1081-9.
21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-8.
22. Xu Y, Song G. The role of CD40-CD154 interaction in cell immu noregulation. J Biomed Sci 2004; 11: 426-38.
23. Chatzigeorgiou A, Lyberi M, Chatzilymperis G, Nezos A, Kamper E. CD40/CD40L signaling and its implication in health and disease. BioFactors 2009; 35: 474-83.
24. Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001; 58: 4-43.
25. Liu Z, Colpaert S, D’Haens GR, et al. Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production. J Immunol 1999; 163: 4049-57.
26. Munroe ME, Bishop GA. A costimulatory function for T cell CD40. J Immunol 2007; 178: 671-82.
27. Yan JC, Ding S, Liang Y, et al. Relationship between upregulation of CD40 system and restenosis in patients after percutaneous coronary intervention. Acta Pharmacologica Sinica 2007; 28: 339.
28. Danese S, Sans M, Scaldaferri F, et al. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal micro circulation: a novel anti-inflammatory mechanism of infliximab in Crohn’s disease. J Immunol 2006; 176: 2617-24.
29. Lin R, Liu J, Gan W, Yang G. C-reactive protein-induced expres sion of CD40-CD40L and the effect of lovastatin and fenofibrate on it in human vascular endothelial cells. Biol Pharm Bull 2004; 27: 1537-43.

APA	Sharifi A, Vahedi H, Honarvar M, Amiriani T, Nikniaz z, yousefi rad e, Hosseinzadeh-Attar M (2020). Vitamin D decreases CD40L gene expression in ulcerative colitis patients: A randomized, double-blinded, placebo-controlled trial. , 99 - 104. 10.5152/tjg.2020.181028
Chicago	Sharifi Amrollah,Vahedi Homayoon,Honarvar Mohammad Reza,Amiriani Taghi,Nikniaz zeinab,yousefi rad esmaeil,Hosseinzadeh-Attar Mohammad Javad Vitamin D decreases CD40L gene expression in ulcerative colitis patients: A randomized, double-blinded, placebo-controlled trial. (2020): 99 - 104. 10.5152/tjg.2020.181028
MLA	Sharifi Amrollah,Vahedi Homayoon,Honarvar Mohammad Reza,Amiriani Taghi,Nikniaz zeinab,yousefi rad esmaeil,Hosseinzadeh-Attar Mohammad Javad Vitamin D decreases CD40L gene expression in ulcerative colitis patients: A randomized, double-blinded, placebo-controlled trial. , 2020, ss.99 - 104. 10.5152/tjg.2020.181028
AMA	Sharifi A,Vahedi H,Honarvar M,Amiriani T,Nikniaz z,yousefi rad e,Hosseinzadeh-Attar M Vitamin D decreases CD40L gene expression in ulcerative colitis patients: A randomized, double-blinded, placebo-controlled trial. . 2020; 99 - 104. 10.5152/tjg.2020.181028
Vancouver	Sharifi A,Vahedi H,Honarvar M,Amiriani T,Nikniaz z,yousefi rad e,Hosseinzadeh-Attar M Vitamin D decreases CD40L gene expression in ulcerative colitis patients: A randomized, double-blinded, placebo-controlled trial. . 2020; 99 - 104. 10.5152/tjg.2020.181028
IEEE	Sharifi A,Vahedi H,Honarvar M,Amiriani T,Nikniaz z,yousefi rad e,Hosseinzadeh-Attar M "Vitamin D decreases CD40L gene expression in ulcerative colitis patients: A randomized, double-blinded, placebo-controlled trial." , ss.99 - 104, 2020. 10.5152/tjg.2020.181028
ISNAD	Sharifi, Amrollah vd. "Vitamin D decreases CD40L gene expression in ulcerative colitis patients: A randomized, double-blinded, placebo-controlled trial". (2020), 99-104. https://doi.org/10.5152/tjg.2020.181028

APA	Sharifi A, Vahedi H, Honarvar M, Amiriani T, Nikniaz z, yousefi rad e, Hosseinzadeh-Attar M (2020). Vitamin D decreases CD40L gene expression in ulcerative colitis patients: A randomized, double-blinded, placebo-controlled trial. Turkish Journal of Gastroenterology, 31(2), 99 - 104. 10.5152/tjg.2020.181028
Chicago	Sharifi Amrollah,Vahedi Homayoon,Honarvar Mohammad Reza,Amiriani Taghi,Nikniaz zeinab,yousefi rad esmaeil,Hosseinzadeh-Attar Mohammad Javad Vitamin D decreases CD40L gene expression in ulcerative colitis patients: A randomized, double-blinded, placebo-controlled trial. Turkish Journal of Gastroenterology 31, no.2 (2020): 99 - 104. 10.5152/tjg.2020.181028
MLA	Sharifi Amrollah,Vahedi Homayoon,Honarvar Mohammad Reza,Amiriani Taghi,Nikniaz zeinab,yousefi rad esmaeil,Hosseinzadeh-Attar Mohammad Javad Vitamin D decreases CD40L gene expression in ulcerative colitis patients: A randomized, double-blinded, placebo-controlled trial. Turkish Journal of Gastroenterology, vol.31, no.2, 2020, ss.99 - 104. 10.5152/tjg.2020.181028
AMA	Sharifi A,Vahedi H,Honarvar M,Amiriani T,Nikniaz z,yousefi rad e,Hosseinzadeh-Attar M Vitamin D decreases CD40L gene expression in ulcerative colitis patients: A randomized, double-blinded, placebo-controlled trial. Turkish Journal of Gastroenterology. 2020; 31(2): 99 - 104. 10.5152/tjg.2020.181028
Vancouver	Sharifi A,Vahedi H,Honarvar M,Amiriani T,Nikniaz z,yousefi rad e,Hosseinzadeh-Attar M Vitamin D decreases CD40L gene expression in ulcerative colitis patients: A randomized, double-blinded, placebo-controlled trial. Turkish Journal of Gastroenterology. 2020; 31(2): 99 - 104. 10.5152/tjg.2020.181028
IEEE	Sharifi A,Vahedi H,Honarvar M,Amiriani T,Nikniaz z,yousefi rad e,Hosseinzadeh-Attar M "Vitamin D decreases CD40L gene expression in ulcerative colitis patients: A randomized, double-blinded, placebo-controlled trial." Turkish Journal of Gastroenterology, 31, ss.99 - 104, 2020. 10.5152/tjg.2020.181028
ISNAD	Sharifi, Amrollah vd. "Vitamin D decreases CD40L gene expression in ulcerative colitis patients: A randomized, double-blinded, placebo-controlled trial". Turkish Journal of Gastroenterology 31/2 (2020), 99-104. https://doi.org/10.5152/tjg.2020.181028